Akiram Therapeutics' drug candidate AKIR001 cleared to start Phase 1 clinical trial
Akiram Therapeutics, a Swedish biotech company specializing in molecular radiation therapy, announces that the Swedish Medical Products Agency has approved the initiation of a Phase 1 clinical trial for its drug candidate [177]Lu-AKIR001. This marks a key milestone in the company’s development of a pioneering cancer treatment aimed at offering new hope for patients with hard-to-treat tumors.Akiram Therapeutics has developed a new type of targeted radioimmunotherapy, [177]Lu-AKIR001. The therapy holds the potential to become a first-in-class treatment in multiple cancer types, including